An Austin-based developer of cystic fibrosis medications has raised $8.6 million to help fund Phase IIa clinical trials for its latest drug.
Savara Pharmaceuticals’ new drug AeroVanc is the first of its kind. AeroVanc is an inhaled antibiotic that aims to treat methicillin-resistant Staphylococcus aureus infections (MRSA) in the lungs, which are particularly dangerous for cystic fibrosis patients. Savara claims AeroVanc can be highly effective.
Savara moved to Austin from Kansas in 2008. The company has four employees but hopes to expand in light of this new funding.
In addition to bacterial infections in the lungs, inhaling dangerous dust particles can also be hazardous to your health. If you want to free your home from dust and other allergens, contact the cleaning technicians of WOW Total Cleaning at 512-291-0048.